Other studies show that Ang-1 and Tie2 levels are predictive biomarkers for better PFS in patients with ovarian cancer who are treated with bevacizumab [22], and that plasma levels of Ang-1, Ang-2 and Tie2 can be considered colorectal cancer biomarkers [23]. The gene discussed is TEK; the disease is ovarian cancer.